India, May 6 -- German Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a loss in its first quarter, compared to prior year's profit with sharply lower net revenues. The company also maintained its fiscal 2024 revenue view.
In pre-market activity on the Nasdaq, BioNTech shares were trading at $88.05, down 5.04 percent.
The year-over-year change was mainly due to lower commercial revenues from the sales of BioNTech's COVID-19 vaccine worldwide resulting from endemic-level demand for COVID-19 vaccines.
For the first quarter, net loss was 315.1 million euros, compared to profit of 502.2 million euros in the prior year period.
Loss per share was 1.31 euros or $1.42, compared to profit of 2.05 eu...